Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Am J Clin Nutr ; 77(6): 1474-7, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12791626

RESUMEN

BACKGROUND: In some patients with vitamin B-12 deficiency mistakenly treated with folic acid, anemia resolved but neurologic complications became worse (masking). Fortification of enriched cereal grains with folic acid has raised concerns that people who consume large quantities of cereal grains, particularly the elderly, may be at increased risk of masking. It is unclear, however, what proportion of people with low vitamin B-12 concentrations do not have anemia and whether the proportion is increasing. OBJECTIVE: We investigated whether fortification has increased the proportion of patients with low vitamin B-12 but without anemia. DESIGN: We reviewed the laboratory results of every patient for whom a vitamin B-12 concentration was measured at the Veterans Affairs Medical Center in Washington, DC, between 1992 and 2000. Those with a low vitamin B-12 concentration (< 258 pmol/L) had their hematocrits and mean cell volumes checked. The proportion without anemia was examined by year before, during, and after folic acid fortification began. RESULTS: There were 1573 subjects with a low vitamin B-12 concentration. The proportion without anemia did not increase significantly from the prefortification period (39.2%) to the period of optional fortification (45.5%) and the postfortification period (37.6%). These findings did not change when the analysis was limited to patients aged > 60 y or when a more conservative definition of low vitamin B-12 (< 150 pmol/L) was used. CONCLUSIONS: Despite evidence that folic acid exposure has increased dramatically since food fortification began, this population showed no evidence of an increase in low vitamin B-12 concentrations without anemia. If confirmed, these results would indicate that food fortification has not caused a major increase in masking of vitamin B-12 deficiency.


Asunto(s)
Grano Comestible , Ácido Fólico/administración & dosificación , Alimentos Fortificados , Deficiencia de Vitamina B 12/epidemiología , Anciano , Anemia , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad
2.
Blood ; 100(9): 3426-8, 2002 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-12384448

RESUMEN

Autoantibodies against factor VIII (FVIII) are rare but can cause life-threatening bleeding requiring costly factor replacement and prolonged immunosuppression. We report 4 consecutively treated patients whose acquired FVIII inhibitors responded rapidly to immunosuppressive regimens that included rituximab, a monoclonal antibody against CD20(+) B cells. Three patients had spontaneously occurring inhibitors. The fourth, a patient with mild hemophilia A, developed both an autoantibody and an alloantibody following recombinant FVIII treatment. Pretreatment FVIII activities ranged from less than 1% to 4% and inhibitor titers from 5 to 60 Bethesda units (BU). One patient with polymyalgia rheumatica who developed the inhibitor while receiving prednisone responded to single agent rituximab. The hemophilia patient had rapid resolution of the autoantibody, whereas the alloantibody persisted for months. Responses continue off treatment from more than 7 to more than 12 months. This report adds to the growing evidence that rituximab has efficacy in immune disorders resulting from autoantibody formation.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/terapia , Factor VIII/inmunología , Hemofilia A/inmunología , Inmunosupresores/uso terapéutico , Isoanticuerpos/inmunología , Adulto , Anciano , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20/inmunología , Autoanticuerpos/biosíntesis , Enfermedades Autoinmunes/etiología , Linfocitos B/inmunología , Factor VIII/antagonistas & inhibidores , Factor VIII/uso terapéutico , Femenino , Hemofilia A/terapia , Humanos , Isoanticuerpos/biosíntesis , Fallo Renal Crónico/complicaciones , Enfermedades Linfáticas/complicaciones , Masculino , Polimialgia Reumática/complicaciones , Polimialgia Reumática/tratamiento farmacológico , Prednisona/administración & dosificación , Prednisona/uso terapéutico , Rituximab
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA